Clinical Trial Update: Daratumumab in HLA Desensitization Prior to Transplantation [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating daratumumab for HLA desensitization prior to heart transplantation, with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)

Snippet

Sponsor: Barry A. Boilson | Conditions: Cardiac Transplant | Phase 2 | Status: ENROLLING_BY_INVITATION